Qiagen (NYSE:QGEN) Position Increased by MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.

MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in shares of Qiagen (NYSE:QGEN) by 3.4% in the fourth quarter, Holdings Channel.com reports. The institutional investor owned 170,957 shares of the company’s stock after buying an additional 5,681 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.’s holdings in Qiagen were worth $7,613,000 at the end of the most recent quarter.

A number of other hedge funds also recently bought and sold shares of the company. Groupama Asset Managment lifted its stake in Qiagen by 8,074.0% during the fourth quarter. Groupama Asset Managment now owns 31,817,740 shares of the company’s stock valued at $1,416,844,000 after buying an additional 32,216,761 shares in the last quarter. Massachusetts Financial Services Co. MA lifted its stake in Qiagen by 9.5% during the fourth quarter. Massachusetts Financial Services Co. MA now owns 25,319,332 shares of the company’s stock valued at $1,127,470,000 after buying an additional 2,202,040 shares in the last quarter. Wellington Management Group LLP lifted its stake in Qiagen by 2.5% during the fourth quarter. Wellington Management Group LLP now owns 21,782,305 shares of the company’s stock valued at $970,534,000 after buying an additional 531,362 shares in the last quarter. Vanguard Group Inc. lifted its stake in Qiagen by 0.9% during the fourth quarter. Vanguard Group Inc. now owns 8,879,089 shares of the company’s stock valued at $397,937,000 after buying an additional 77,119 shares in the last quarter. Finally, Norges Bank purchased a new stake in Qiagen during the fourth quarter valued at about $181,529,000. 70.00% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of analysts have commented on QGEN shares. UBS Group reduced their price objective on shares of Qiagen from $50.00 to $48.00 and set a “neutral” rating for the company in a research note on Friday, February 7th. Robert W. Baird raised their price target on shares of Qiagen from $42.00 to $43.00 and gave the stock a “neutral” rating in a report on Monday, April 21st. StockNews.com upgraded shares of Qiagen from a “buy” rating to a “strong-buy” rating in a report on Thursday. Baird R W cut shares of Qiagen from a “strong-buy” rating to a “hold” rating in a report on Wednesday, February 19th. Finally, Redburn Atlantic cut shares of Qiagen from a “buy” rating to a “neutral” rating in a report on Friday, April 4th. Seven investment analysts have rated the stock with a hold rating, three have issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, Qiagen currently has an average rating of “Hold” and an average target price of $48.42.

Qiagen Price Performance

Shares of QGEN opened at $42.65 on Friday. The firm has a market cap of $9.48 billion, a PE ratio of 118.76, a PEG ratio of 2.39 and a beta of 0.67. The firm’s 50 day moving average price is $40.97 and its 200 day moving average price is $41.81. The company has a debt-to-equity ratio of 0.38, a quick ratio of 3.09 and a current ratio of 3.61. Qiagen has a twelve month low of $37.63 and a twelve month high of $49.30.

Qiagen (NYSE:QGEN) last issued its quarterly earnings data on Wednesday, May 7th. The company reported $0.55 earnings per share for the quarter, beating the consensus estimate of $0.50 by $0.05. The firm had revenue of $483.46 million for the quarter, compared to analyst estimates of $465.66 million. Qiagen had a net margin of 4.23% and a return on equity of 13.92%. The company’s revenue for the quarter was up 5.2% on a year-over-year basis. During the same quarter last year, the firm earned $0.44 earnings per share. As a group, research analysts expect that Qiagen will post 2.26 EPS for the current fiscal year.

Qiagen Company Profile

QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials.